Glaukos Corp（GKOS）の財務GKOSGlaukos Corp

Glaukos Corporation (GKOS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Glaucoma, accounting for 83.6% of total sales, equivalent to $155.18M. Another important revenue stream is Corneal Health. Understanding this composition is critical for investors evaluating how GKOS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Glaukos Corporation maintains a gross margin of 85.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.39%, while the net margin is 0.96%. These profitability ratios, combined with a Return on Equity (ROE) of -22.84%, provide a clear picture of how effectively GKOS converts its operational activities into shareholder value.

In the context of the broader market, GKOS competes directly with industry leaders such as QGEN and PODD. With a market capitalization of $10.69B, it holds a leading position in the sector. When comparing efficiency, GKOS's gross margin of 85.23% stands against QGEN's 63.28% and PODD's 70.18%. Such benchmarking helps identify whether Glaukos Corporation is trading at a premium or discount relative to its financial performance.

Glaukos reported a Q2 2026 revenue of $185.6 million, a 50% year-over-year increase, and raised its 2026 revenue guidance to between $680 million and $700 million, showcasing strong growth prospects.